L. Magnano

A framework to challenge the dogma of incurability in follicular lymphoma.

Follicular lymphoma (FL) has traditionally been considered an incurable malignancy characterized by repeated relapses. However, emerging long-term data are increasingly challenging this paradigm. With rituximab, median overall survival approaches 20 years, and only 35-40% of patients require more than one treatment lin...